Skip to main content
TRDA logo

Entrada Therapeutics, Inc.

TRDANASDAQHealthcareBiotechnology

$4.41Today:- (-)1Y −26.09%

As of Oct 27, 2026 close

Market cap
$186.20M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$4.11$16.45
Volume (live)
-
Avg. volume (3M)
367.11K

Entrada Therapeutics (TRDA) Financial Ratios

For fiscal 2025 (fiscal year ended Dec 31, 2025), Entrada Therapeutics had return on equity of -39.1% (down from 19.6%), debt-to-equity of 0.17 (up from 0.14), a current ratio of 12.53 (up from 11.14) and return on assets of -21.6% (down from 5.9%). A current ratio of 12.53 means current assets exceed current liabilities.

Entrada Therapeutics Financial Ratios Analysis

Valuation, profitability, leverage, and liquidity ratios

Scroll to see more
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Valuation Ratios
P/E Ratio-9.33----
P/S Ratio14.502.903.90---
P/B Ratio1.201.432.081.991.79-
Price/Tangible Book1.201.432.081.991.79-
Price/FCF--3.75---
Price/OCF--3.60---
Enterprise Value Ratios
EV/Revenue3.711.061.69---
EV/EBITDA-4.41----
EV/EBIT-4.77----
EV/FCF--1.63---
Profitability & Returns
Return on Equity (ROE)-39.13%19.56%-2.94%-37.01%-30.19%-93.94%
Return on Assets (ROA)-21.58%5.90%-0.55%-21.79%-18.29%-53.97%
Return on Invested Capital (ROIC)-241.38%350.11%41.75%-338.65%-1165.02%-9243.33%
Return on Capital Employed (ROCE)-44.20%9.70%-1.00%-42.30%-17.10%-66.40%
Leverage & Solvency Ratios
Debt/Equity0.170.140.280.12--
Debt/EBITDA-0.924.68---
Debt/FCF--0.51---
Liquidity Ratios
Current Ratio12.5311.142.339.5544.4611.89
Quick Ratio12.2010.782.268.6243.3211.62
Efficiency Ratios
Asset Turnover0.060.420.36---
Yield & Distribution Ratios
Earnings Yield-38.99%10.72%-1.33%-22.33%-9.57%-
FCF Yield-35.14%-7.30%26.68%-22.82%-10.37%-
Buyback Yield-6.07%-18.01%-5.61%-399.27%-467.09%-18.45%

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Entrada Therapeutics Financial Ratios

What is Entrada Therapeutics's return on equity?

Entrada Therapeutics's return on equity (ROE) was -39.1% for fiscal 2025 (period ended Dec 31, 2025). It was 19.6% a year earlier.

What is Entrada Therapeutics's debt-to-equity ratio?

Entrada Therapeutics's debt-to-equity ratio was 0.17 for fiscal 2025 (period ended Dec 31, 2025). It was 0.14 a year earlier.

What is return on equity (ROE)?

Return on equity is net income divided by shareholders' equity. It measures how much profit a company generates from the capital its shareholders have invested. Full definition